m RNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say - Ars Technica

Overview

m RNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck sayvar abtest_2168315 = new ABTest(2168315, 'click');

The vaccine reportedly thwarted the cancer’s return and spread.

Details

Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel m RNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer.

The announcement was scant on details, but if the success holds, it stands to realize the high aspirations for both m RNA vaccines and individualized cancer-targeting medicines in cancer therapy, providing a first success for both treatment types.

The Phase 3 trial included 1,137 patients who had stage IIB–IV melanoma that had been surgically removed prior to their treatment in the trial. Patients were randomized two-to-one to receive either a combination treatment of the tailored m RNA vaccine (intismeran or m RNA-4157) with Merck’s established monoclonal antibody cancer treatment Keytruda, or they received treatment with Keytruda alone. Both patient groups were treated for about a year. The trial was placebo-controlled and double-blind, meaning neither the doctors nor the patients knew which treatment patients were randomly assigned to receive.

Based on a planned interim analysis, Moderna and Merck report that the combination therapy with the m RNA vaccine extended “recurrence-free survival” (RFS), which is the amount of time a patient has without the cancer returning. The combination therapy also extended “distant metastasis-free survival” (DMFS), which is the amount of time a patient has without the cancer returning and occurring in a different part of the body than where it began.

The companies say the extensions of RFS and DMFS reported were statistically significant and clinically meaningful, but they did not elaborate. They said the data will be presented at an upcoming international medical conference. They did note, however, that data from a five-year Phase 2 trial, which was presented at a cancer researcher conference in June, showed a 49 percent reduction in the risk of recurrence or death and a 59 percent reduction in the risk of distant metastasis or death.

The m RNA vaccine intismeran works using a synthetic m RNA that holds the unique genetic coding for up to 34 mutations in a patient’s own cancer cells. The production process involves comparing the genetic sequences of a patient’s cancer cells to those of healthy cells and picking out any cancer-specific mutations that could help the immune system differentiate cancer cells from healthy ones.

Using the same platform Moderna used for its m RNA COVID-19 vaccine, intismeran delivers to healthy cells the m RNA code for those mutations. Healthy cells translate that m RNA code into protein fragments representing the cancer mutations, and then those fragments are presented to immune cells as antigens, a foreign substance to attack. As such, Moderna and Merck call their m RNA cancer vaccine a type of “neoantigen therapy.”

The term avoids both “m RNA” and “vaccine,” which draw hostility from Trump’s anti-vaccine Health Secretary Robert F. Kennedy Jr. In addition to his concerted efforts to undermine lifesaving vaccines, Kennedy has canceled hundreds of millions of dollars in federal grants for the development of m RNA vaccine technology.

In the companies’ announcement, Georgina Long, who led the trial, said the results were “a landmark moment” with the “potential to establish a new treatment paradigm.” Dean Li, president of Merck Research Laboratories, said the findings “reinforce the promise of a more personalized approach to cancer treatment.” Moderna CEO Stéphane Bancel, meanwhile, highlighted m RNA technology’s role, saying this is “a pivotal moment for the field of cancer research.”

“For many years, the idea of creating an m RNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality,” Bancel said.

Despite the lack of details, outside experts are similarly hopeful and encouraged by the announcement. “This is the first positive Phase III trial of an individualized neoantigen therapy and an m RNA-based cancer treatment,” University of Oxford cancer expert Lennard Lee said in a statement. “That makes this an important moment for a field that scientists have been working towards for many years. Within six years of the pandemic, we have m RNA vaccines to treat cancer,” he said, also calling it “very encouraging” and “significant.”

Lee, however, highlighted that we don’t yet know the magnitude of the benefit, the detailed subgroup analyses, quality-of-life data, or mature overall-survival results. “Those details will allow the scientific and clinical community to understand precisely how large the benefit is, which patients benefit most, and ultimately where this treatment might sit within routine melanoma care,” he said.

1.          Against all odds, Space X finally tugs Starship into port after 24 days at sea
   

2.          The United States is about to wake up to the threat from China's space program
   

3.          "Sabotage": Experts, lawmakers blast RFK Jr. for destroying healthcare research
   

4.          Satellite operators are in panic mode due to a worsening launch crisis
   

5.          Ukrainian drones overwhelm Russian tanks’ new active protection system—for now
   

Ars Technica has been separating the signal from the noise for over 25 years. With our unique combination of technical savvy and wide-ranging interest in the technological arts and sciences, Ars is the trusted source in a sea of information. After all, you don’t need to know everything, only what’s important.

Key Takeaways

• m RNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck sayvar abtest_2168315 = new ABTest(2168315, 'click');

• The vaccine reportedly thwarted the cancer’s return and spread

• Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel m RNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer

• The announcement was scant on details, but if the success holds, it stands to realize the high aspirations for both m RNA vaccines and individualized cancer-targeting medicines in cancer therapy, providing a first success for both treatment types

• The Phase 3 trial included 1,137 patients who had stage IIB–IV melanoma that had been surgically removed prior to their treatment in the trial